comparemela.com
Home
Live Updates
Vepdegestrant Shows Potential in ESR1-Mutant ER+/HER2– Breast Cancer : comparemela.com
Vepdegestrant Shows Potential in ESR1-Mutant ER+/HER2– Breast Cancer
Debu Tripathy, MD, highlights the potential role and significance of vepdegestrant in pretreated ER-positive/HER2-negative breast cancer.
Related Keywords
Corrs
,
Texas
,
United States
,
Houston
,
,
University Of Texas Md Anderson Cancer Center
,
Division Of Cancer Medicine
,
Department Of Breast Medical Oncology
,
Arvinas Inc
,
Pfizer
,
Debu Tripathy
,
Antonio Breast Cancer Symposium
,
Breast Medical Oncology
,
Cancer Medicine
,
Cancer Center
,
D
,
Vepdegestrant
,
Pretreated Er Positive Her2 Negative Breast Cancer
,
The University Of Texas Md Anderson Cancer Center
,
comparemela.com © 2020. All Rights Reserved.